Zai Lab Ltd (ASX: 09688) shares climbed more than 12% in morning trading. As of press time, the stock was up 11.77% at HK$20.52, with a turnover of HK$51,308,780.

Zai Lab Ltd recently disclosed its third-quarter 2026 results. During the reporting period, the company's total revenue reached US$108.2 million, of which net product revenue amounted to US$107.6 million, representing a 2% increase sequentially, primarily driven by expanded market coverage and penetration of Nuzyra as well as the launch of KarXT.

On the innovative drug research and development front, Zai Lab Ltd's independently developed DLL3-targeting ADC drug zocilurtatug pelitecan (zoci) is the company's most advanced core pipeline asset. Dr. Ying Du, Founder, Chairwoman, and Chief Executive Officer of Zai Lab Ltd, stated that the strong data from the first-line combination therapy for zoci presented at the ESMO Congress reinforced the company's confidence in its potential to become the preferred cornerstone ADC for small cell lung cancer. The year 2027 will be a pivotal year, as the company expects to submit its first Biologics License Application (BLA) for zoci in the United States.